Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Dry Skin Cream, Lotion, and Ointment MarketThe global dry skin cream, lotion, and ointment market is on the cusp of substantial expansion, according to recent market analysis. The industry is ...

AnaptysBio to abandon eczema drug development after mid-stage ... has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as ...

In a carbon copy of 2023’s results, the 2024 list features AbbVie’s Skyrizi and Rinvoq in the top two spots, followed by yet another immunology giant, Sanofi and Regeneron’s Dupixent ...

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission. On a good day, your skin might be calm and glowy—but if you’re dealing with ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.